Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2012. The report details a specific share repurchase transaction executed on September 11, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 1,700,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,431.5 pence per share; lowest price paid was 1,417.0 pence per share.
- Treasury Holdings (Settled): 509,482,427 shares, representing 9.31% of total issued share capital.
- Treasury Holdings (Including Unsettled): 514,715,427 shares, representing 10.37% of current total voting rights.
- Shares in Issue (Excluding Treasury): 4,962,940,555 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 1,700,000 shares on September 11, 2012. Consequently, the percentage of shares held in Treasury increased to 10.37% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total cost of the 1,700,000 share repurchase based on the reported price range.
- Confirm the impact of the 10.37% treasury holding on the denominator for shareholder notification thresholds under Disclosure and Transparency Rules.
- Check subsequent filings for the settlement status of the shares purchased but not yet settled at the time of this report.